Effects of somatostatin analogues on acromegalic cardiomyopathy: Results from a prospective study using cardiac magnetic resonance

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03346562PMID 20348836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging

  2008cited by this paper
• Identification, treatment and management of cardiovascular risks in patients with acromegaly

  2008cited by this paper
• MRI to Assess Arrhythmia and Cardiomyopathies: Relationship to Echocardiography

  2007cited by this paper
• Prevalence and functional significance of antipituitary antibodies in patients with autoimmune and non-autoimmune thyroid diseases.

  2007cited by this paper
• Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.

  2007cited by this paper
• Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease.

  2007cited by this paper
• The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly

  2007cited by this paper
• Myocardial systolic strain abnormalities in patients with acromegaly: A prospective color Doppler imaging study

  2006cited by this paper
• First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group

  2006cited by this paper
• Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy.

  2006cited by this paper
• Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance.

  2006cited by this paper
• Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy

  2005cited by this paper
• MRI of the Heart and Vessels

  2005cited by this paper
• Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study

  2005cited by this paper
• Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

  2004cited by this paper
• Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography

  2004cited by this paper
• Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report.

  2004cited by this paper
• Cardiovascular function in acromegaly.

  2003cited by this paper
• Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady‐state free precession imaging sequences

  2003cited by this paper
• Diagnosis and treatment of acromegaly complications

  2003cited by this paper
• Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide

  2003cited by this paper
• Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly.

  2002cited by this paper
• Treatment of acromegaly improves myocardial abnormalities.

  2002cited by this paper
• Growth hormone and the heart

  2001cited by this paper
• Cardiovascular Complications in Acromegaly: Methods of Assessment

  2001cited by this paper
• A comparison of MRI and echocardiography in hypertrophic cardiomyopathy.

  1999cited by this paper
• Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients.

  1999cited by this paper
• Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.

  1999cited by this paper
• Blood pressure-independent cardiac hypertrophy in acromegalic patients.

  1999cited by this paper
• Cardiovascular aspects in acromegaly: effects of treatment.

  1996cited by this paper
• Growth hormone and the heart.

  1994cited by this paper
• Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.

  1994cited by this paper
• Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

  1993cited by this paper
• Cardiac hypertrophy and function in asymptomatic acromegaly.

  1991cited by this paper

• Cardiovascular Effects of Growth Hormone: From Deficiency to Acromegaly.

  2026cites this paper
• Gender differences in the glycometabolic and cardiovascular features of acromegaly

  2026cites this paper
• Cardiac structure and function recovery in acromegaly after treatment: insights from cardiac magnetic resonance imaging

  2025cites this paper
• The effect of first intervention on cardiac parameters in patients with acromegaly: a systematic review.

  2025cites this paper
• An Overview of Cardiovascular Risk in Pituitary Disorders

  2024cites this paper
• Effects of acromegaly treatment on left ventricular systolic function assessed by speckle tracking echocardiography in relation to sex differences: results from a prospective single center study

  2023cites this paper
• Use of speckle tracking echocardiography in evaluating cardiac dysfunction in patients with acromegaly: an update

  2023cites this paper
• Advances in Research on the Cardiovascular Complications of Acromegaly

  2021cites this paper
• Association between fragmented QRS and left ventricular dysfunction in acromegaly patients

  2020cites this paper
• Cardiac Abnormalities in Acromegaly Patients: A Cardiac Magnetic Resonance Study

  2020cites this paper
• Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly.

  2020cites this paper
• Secondary Hypertension

  2020cites this paper
• Reversibility of Cardiac Involvement in Acromegaly Patients After Surgery: 12-Month Follow-up Using Cardiovascular Magnetic Resonance

  2020cites this paper
• Hypertension in Acromegaly

  2020cites this paper
• Cardiomyopathie du diabétique, dépistage et épidémiologie

  2019cites this paper
• Acromegaly and Heart Failure.

  2019cites this paper
• Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review

  2019influential citation
• Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

  2019cites this paper
• Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature

  2018cites this paper
• Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options

  2018cites this paper
• Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.

  2018cites this paper
• ASSESSMENT OF DIASTOLIC DYSFUNCTION, ARTERIAL STIFFNESS, AND CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH ACROMEGALY.

  2017cites this paper
• The role of neuropeptides in adverse myocardial remodeling and heart failure

  2017cites this paper
• Impact of acromegaly treatment on cardiovascular complications

  2017cites this paper
• Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment

  2016cites this paper
• Update on Echocardiographic Assessment in Diabetes Mellitus

  2016cites this paper
• The Emerging Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Metabolic Cardiomyopathies

  2015cites this paper
• Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort.

  2015cites this paper
• Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues

  2015cites this paper
• No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy.

  2014cites this paper
• Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study

  2014cites this paper
• The cardiovascular system in growth hormone excess and growth hormone deficiency

  2012cites this paper
• [Acromegalic cardiomyopathy].

  2011cites this paper